Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

January 25, 1999

Primary Completion Date

July 31, 2002

Conditions
Ovarian CancerTesticular Germ Cell Tumor
Interventions
DRUG

gemcitabine hydrochloride

DRUG

paclitaxel

Trial Locations (19)

14642

University of Rochester Cancer Center, Rochester

46202

Veterans Affairs Medical Center - Indianapolis (Roudebush), Indianapolis

54449

CCOP - Marshfield Medical Research and Education Foundation, Marshfield

55416

CCOP - Metro-Minnesota, Saint Louis Park

60611

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago

Veterans Affairs Medical Center - Chicago (Lakeside), Chicago

61801

CCOP - Carle Cancer Center, Urbana

70121

CCOP - Ochsner, New Orleans

80209-5031

CCOP - Colorado Cancer Research Program, Inc., Denver

46202-5265

Indiana University Cancer Center, Indianapolis

52403-1206

CCOP - Cedar Rapids Oncology Project, Cedar Rapids

02215

Beth Israel Deaconess Medical Center, Boston

49007-3731

CCOP - Kalamazoo, Kalamazoo

07601

Hackensack University Medical Center, Hackensack

08701

Kimball Medical Center, Lakewood

07962-1956

Morristown Memorial Hospital, Morristown

44106-5065

Ireland Cancer Center, Cleveland

19102-1192

Hahnemann University Hospital, Philadelphia

0001

Pretoria Academic Hospital, Pretoria

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Eastern Cooperative Oncology Group

NETWORK

NCT00003518 - Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors | Biotech Hunter | Biotech Hunter